Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics

Merck has entered a discovery collaboration with Quotient Therapeutics, committing $20 million upfront to access Somatic Genomics, an AI-enabled platform that analyzes somatic mutations directly in patient tissues. The agreement focuses on identifying new drug targets for inflammatory bowel disease (IBD), with potential milestone payments bringing the total deal value to $2.2 billion.